5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021)

Record Type:: Journal Article
Title:: 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021)
Main Title:: 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
Authors:: Gligorov, J.
Pivot, X.
Ataseven, B.
De Laurentiis, M.
Llombart, A.
Jung, K.H.
Manikhas, A.
Azim, H.A.
Alexandrou, A.
Gupta, K.
Herraez-Baranda, L.
Tosti, N.
Restuccia, E.
Abstract:
Is Part Of:: Breast. Volume 56(2021)Supplement 1
Journal:: Breast
Issue:: Volume 56(2021)Supplement 1
Issue Display:: Volume 56, Issue 2021 (2021)
Year:: 2021
Volume:: 56
Issue:: 2021
Issue Sort Value:: 2021-0056-2021-0000
Page Start:: S21
Page End:: S22
Publication Date:: 2021-04
Subjects:: Breast -- Diseases -- Periodicals
Breast -- Tumors -- Periodicals
Breast -- Periodicals
Electronic journals
Periodicals
616
Journal URLs:: http://www.sciencedirect.com/science/journal/09609776 ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0960-9776;screen=info;ECOIP ↗
http://www.harcourt-international.com/journals/brst/ ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09609776 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09609776 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0960-9776(21)00097-7 ↗
Languages:: English
ISSNs:: 0960-9776
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 2277.492700
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 16181.xml